Why Cholesterol and Alzheimer’s Could Drive Eli Lilly Shares Much Higher
Credit Suisse sees solid upside in this company Eli Lilly as the result of a strong pipeline, with its Alzheimer's candidate as a potential blockbuster.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 243UBS Loves These 3 Top Biotech Stock Leaders Into Q3 Earnings
Given the massive beat-down in the sector, if these companies surpass earnings expectations, the upside could be sizable.
Generics Giants Like Teva and Mylan May Now Join the Buy-and-Raise Craze
Martin Shkreli has said he would lower the price of Daraprim back down but hasn’t actually done it. He probably figures that if he can outlast the initial wave of negative publicity, people will…
What Johns Hopkins Study Reveals About Premature Births Near Fracking Wells
A new study published recently by the Johns Hopkins University Bloomberg School of Public Health has linked an increase in premature births to a mother’s proximity to active, fracked natural gas wells.
Acelity Aims for Massive IPO
Acelity Holdings has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Hot Political Rhetoric Hammers Specialty Pharmaceuticals: 3 to Buy Now
We scanned the Merrill Lynch stock coverage universe for specialty pharmaceutical stocks rated Buy and found three top companies that have been crushed.
Neurocrine Bio Soars on Positive Phase 3 Results
Neurocrine Biosciences made waves in the market on Thursday morning after it announced positive results in a Phase 3 trial.
Why Mallinckrodt Shares Could Double
ThinkstockMallinckrodt PLC (NYSE: MNK) has been making waves in the market recently related to its guidance and it has caught the attention of one key analyst. Oppenheimer weighed in on Mallinckrodt in its most recent…
Aclaris Enters Market Well Below Expected Range in IPO
Aclaris Therapeutics debuted on the market in its initial public offering (IPO) on Wednesday morning.
Why Merrill Lynch Now Favors Large Cap Leaders in Biotech
These four top large cap biotechs are very good bets for investors looking to add high-quality companies with less volatility and binary clinical data risk.
Why Sarepta Deserves Praise for Capital Raise Despite Stock Drop
Sarepta announced a public offering of more than 3 million shares of its common stock at a price to the public of $39.00 per share, with a value of up to more than $145…
Can ContraVir Sustain This Move in a Shaky Health Care Sector?
ContraVir Pharmaceuticals led the bulls’ charge in the market on Monday, with shares practically doubling in what was thought to be a shaky health care sector.
3 Biotech Stocks Loved by Portfolio Managers Now
A new report from Cowen points out that many skittish portfolio managers are anxiously awaiting third-quarter numbers to make sure that the biotech thesis is still in place.
Why Spark Therapeutics Is Up Over 50%
Spark Therapeutics made history Monday morning when it announced successful Phase 3 results in gene therapy for a genetic disease.
5 Big FDA Decisions Expected in October
24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of October and added some color.